OR WAIT null SECS
Upon completion of five-year project, the location will serve as Asian hub for dose manufacturing
Sanofi will be investing $476 million (€400 million) over five years to create a vaccine production center in Singapore. In partnership with the Singapore Economic Development Board (EDB), the new site will supply the Asian region and supplement existing manufacturing efforts in Europe and North America.
The project is currently entering its design phase with construction expected to begin in Q3 of this year. The five-year project will see the site fully operational in Q1 2026, once all qualifications and validations of the first manufactured vaccine have been completed. Sanofi currently has two Covid-19 vaccine candidates in the works, and has already provided its production services to various other big pharma manufacturers, including Pfizer-BioNTech and Johnson & Johnson.
This factory will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines at the same time, as opposed to one in current industrial sites. Further, the factory will have the flexibility to control multiple vaccine manufacturing technology platforms based on different cell types. This will allow the production of a specific vaccine to be prioritized in a faster timeframe depending on public health needs, Sanofi says.
The Singapore site is designed to be carbon-neutral, which will help reduce resource and waste production.